(Q34387423)

1 August 2017

1 reference

title

Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment (English)

1 reference

1 August 2017

1

Ayalew Tefferi

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

1 August 2017

1 reference

1 August 2017

volume

80

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

75-83

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

1 August 2017

1 reference

Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

The chemokine network in eosinophil activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Mechanisms of eosinophil adherence to cultured vascular endothelial cells. Eosinophils bind to the cytokine-induced ligand vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

The biology of the eosinophilic leukocyte

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Mechanism of membrane damage mediated by human eosinophil cationic protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Neurotoxicity of human eosinophils towards peripheral nerves

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Eosinophilic vasculitis in connective tissue disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Eosinophils from hypereosinophilic patients damage endocardium of isolated feline heart muscle preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

The eosinophilias, including the idiopathic hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

t(5;9)(q11;q34): a novel familial translocation involving Abelson oncogene and association with hypereosinophilia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Familial eosinophilia: a benign disorder?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Diagnostic and clinical aspects of schistosomiasis in 182 patients treated at a Swedish ward for tropical diseases during a 10-year period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Visceral larva migrans. A review and reassessment indicating two forms of clinical expression: visceral and ocular

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Fascioliasis in developed countries: a review of classic and aberrant forms of the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Comparison of human trichinellosis caused by Trichinella spiralis and by Trichinella britovi.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Borrelial fasciitis: diffuse fasciitis and peripheral eosinophilia associated with Borrelia infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Eosinophilia in patients infected with the human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

DRESS syndrome associated with HHV-6 reactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Carbamazepine and eosinophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Eosinophilia resulting from administration of recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in a patient with T-gamma lymphoproliferative disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

GM-CSF-induced acute eosinophilic pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Tryptophan-associated eosinophilic connective-tissue disease. A new clinical entity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Toxic oil syndrome: a current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Eosinophilia in toxic shock syndrome: review of 20 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Blood eosinophil number and activity in relation to lung function in patients with asthma and with eosinophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Blood eosinophilia in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Pulmonary eosinophilia with and without allergic bronchopulmonary aspergillosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Blood eosinophilia in Hodgkin's disease. A follow-up of 25 cases in Venezuela

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

B-cell lymphoma associated with eosinophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Malignant lymphomas of B-cell lineage with marked tissue eosinophilia. A report of five cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Metastatic Carcinoma Presenting with Concomitant Eosinophilia and Thromboembolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Metastatic squamous cell carcinoma with marked blood eosinophilia and elevated serum interleukin-5 levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Paraneoplastic eosinophilia. Report of a case with in vitro studies of hemopoiesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Acute myelogenous leukemia (FAB M1) associated with t(5;16) and eosinophilia. Report of an additional case

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Myelodysplastic syndrome with clonal eosinophilia accompanied by eosinophilic pulmonary interstitial infiltration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Cytogenetic and molecular genetic aspects of eosinophilic leukaemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Eosinophilia in systemic mastocytosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Mechanism of action and in vivo role of platelet-derived growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Systemic mast cell disease presenting with peripheral blood eosinophilia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical, immunological and cytogenetic features and therapeutic approach. A case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Receptor tyrosine kinase mutations in myeloid neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Identification of four new translocations involving FGFR1 in myeloid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

State of the art; the hypereosinophilic syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Evolution to eosinophilic leukemia with a t(5:11) translocation in a patient with idiopathic hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Abnormal Clones of T Cells Producing Interleukin-5 in Idiopathic Eosinophilia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Dermatologic Manifestations of the Hypereosinophilic Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Wells' syndrome associated with idiopathic hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Neuropathy in the hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Neurologic dysfunction in the idiopathic hypereosinophilic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Eosinophilic meningitis and the hypereosinophilic syndrome. Case report and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Idiopathic hypereosinophilic syndrome-related pulmonary involvement diagnosed by bronchoalveolar lavage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Pulmonary involvement in the hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Pulmonary involvement of idiopathic hypereosinophilic syndrome: CT findings in five patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Hypereosinophilic syndrome resembling chronic inflammatory bowel disease with primary sclerosing cholangitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Hepatic vein obstruction in idiopathic hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Ophthalmologic abnormalities in the hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Renal involvement in a patient with idiopathic hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Clinical, genetic, and therapeutic insights into systemic mast cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

STI571 inhibits growth and adhesion of human mast cells in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Imatinib for systemic mast-cell disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Therapy of the hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Cyclosporin for hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Response of six patients with idiopathic hypereosinophilic syndrome to interferon alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Treatment of hypereosinophilic syndrome with imatinib mesilate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Overriding imatinib resistance with a novel ABL kinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

The clinical and immunologic responses of normal human volunteers to low dose hookworm (Necator americanus) infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Sclerosing cholangitis associated with hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

inferred from DOI database lookup

7 January 2021

based on heuristic

2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2811%2962962-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-6196(11)62962-5

0 references

1 reference